AI Assistant
Blog
Pricing
Log In
Sign Up
Do RARA/PML fusion gene deletions confer resistance to ATRA-based therapy in patients with acute promyelocytic leukemia?
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
